Seattle-based biotech firm Omeros says its pipeline treatment to rival Alexion's Soliris is set to enter phase 3 later this year. Alexion's Soliris (eculizumab) is a blockbuster, earning $2.5 billion ...
The European Commission has granted an orphan drug designation to Alexion Pharmaceuticals’ Soliris (eculizumab) to prevent graft rejection in organ transplants. The European Commission has granted an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback